The drumbeat of innovation in the heart valves space continues as companies pursue next-generation devices for easier implantation, to improve durability and to treat younger patients. Even though ...

South San Francisco-based Trex Bio Inc. priced its IPO of about 8.3 million shares at $14 per share for about $116.7 million to finance efforts taking aim at a pair of targets hardly unfamiliar to the ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, ...

Several initiatives the U.S. Department of Health and Human Services (HHS) announced Oct. 8 continue to shift the government’s vaccine focus from disease prevention to vaccine harm. Strengthening “how ...

In the last five years, public markets in Europe have been a no-go area for biotechs, and for U.K. companies the situation is dire, with the way barred to new entrants and a lack of liquidity leading ...

Vinci Pharmaceuticals Inc. has closed a series A financing round raising over $8 million as the company advances development of its Epiplant delivery platform.

Despite their clinical success, real-world data suggest that GLP-1 receptor agonists may be limited by challenges, driving interest in complementary mechanisms that target the underlying metabolic ...

Persistent mycobacterial infections may depend on senescent macrophages that provide a long-term intracellular refuge to ...

Tsinghua University has patented new antibody-drug conjugates consisting of a monoclonal antibody targeting immune checkpoint and/or tumor antigen molecule covalently bound to a small molecule ...

Ningbo Jiefu Biotechnology Co. Ltd. has identified new epidermal growth factor receptor (EGFR; ERBB1; HER1) inhibitors and EGFR protein/nucleic acid degraders potentially useful for the treatment of ...

Researchers at CHA University and Ewha Womans University have disclosed new cathepsin S inhibitors potentially useful for the treatment of fibrosis, cancer, metabolic diseases, cardiovascular and ...